



Biogen Idec and Eisai Announce Manufacturing Alliance at Research Triangle Park Facilities

December 12, 2012

-- Deal Leverages Complementary Strengths for Both Research Triangle Park Employers --

-- Reinforces Local Presence through Increased Capacity Utilization --

RESEARCH TRIANGLE PARK, N.C.--([BUSINESS WIRE](#))--[Biogen Idec](#) (NASDAQ: BIIB) and [Eisai Inc.](#) today announced a strategic alliance that will bolster the manufacturing capabilities of both companies' Research Triangle Park (RTP)-based facilities. Under the terms of the agreement, Biogen Idec will lease a portion of the Eisai facility to manufacture oral solid dose products for both companies. Eisai will provide Biogen Idec with vial-filling services for biologic therapies and packaging services for oral solid dose products. The 10-year lease agreement gives Biogen Idec the option to purchase the Eisai oral solid dose facility.

"We view our supply chain as a lifeline to patients, designed to deliver quality therapies wherever and whenever they are needed," said John G. Cox, executive vice president of Pharmaceutical Operations and Technology, for Biogen Idec. "This innovative capacity-sharing relationship with Eisai fits strategically in our global drug supply network, particularly as we advance our oral therapeutics."

Approximately 50 Eisai personnel are expected to become Biogen Idec employees in early 2013, building on the company's RTP workforce which exceeded 1,000 in 2012. Eisai currently employs approximately 225 full-time employees at its RTP site.

"We look forward to collaborating with Biogen Idec to continue the proud history of drug manufacturing excellence here at our RTP site," said Lou Arp, general manager of the Eisai RTP site and president of Global Oncology Manufacturing, for Eisai Inc. "Our alliance will enable both companies to focus on respective areas of expertise while continuing to deliver high-quality and innovative products to patients. Moreover, employees will benefit by working in a highly collaborative environment that offers opportunities to further cultivate their careers."

Biogen Idec and Eisai have both operated manufacturing facilities in RTP since the mid-1990s. "This alliance underscores the Triangle region's reputation as a globally competitive location for life sciences," said Bob Geolas, president and CEO of the Research Triangle Foundation. "In addition, it's an illustration of the type of collaboration we encourage and foresee becoming more commonplace as the Park moves forward with its new Master Plan."

About Biogen Idec

Through cutting-edge science and medicine, Biogen Idec discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. Founded in 1978, Biogen Idec is the world's oldest independent biotechnology company. Patients worldwide benefit from its leading multiple sclerosis therapies, and the company generates more than \$5 billion in annual revenues. For product labeling, press releases and additional information about the company, please visit www.biogenidec.com.

About Eisai Inc.

Eisai Inc. was established in 1995 and began marketing its first product in the United States in 1997. Since that time, Eisai Inc. has rapidly grown to become a fully integrated pharmaceutical business. Eisai's key areas of commercial focus are neurology and oncology. The company serves as the U.S. pharmaceutical operation of Eisai Co., Ltd., a research-based human health care (hlc) company that discovers, develops and markets products throughout the world. Eisai has a global product creation organization that includes U.S.-based R&D facilities in Massachusetts, New Jersey, North Carolina and Pennsylvania, as well as manufacturing facilities in Maryland and North Carolina. The company's areas of R&D focus include neuroscience; oncology; vascular, inflammatory and immunological reaction; and antibody-based programs. For more information about Eisai, please visit www.eisai.com/US.

Contact:

Biogen Idec Media Contact:
Mike McBrierty, 919-993-6368
Senior Manager, Public Affairs

or
Biogen Idec Investor Contact:
Benjamin Strain, 781-464-2442
Senior Manager, Investor Relations

or
Eisai Inc. Media Contact:
Lynn Kenney, 201-746-2294
Senior Director, Corporate Communications

or
Eisai Inc. Investor Contact:
Alex Scott, 201-746-2177
Vice President, Commercial Development